Recombinant MS4A1 (Rituximab Biosimilar) antibody
Quick Overview for Recombinant MS4A1 (Rituximab Biosimilar) antibody (ABIN7795085)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Rituximab Biosimilar, Endotoxin 0.05 EU/mg
-
Characteristics
- B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues. Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Endotoxin Level
- Less than 0.5 EU/mg of protein as determined by LAL method
-
Immunogen
- Human lymphoblastoid cell line SB
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- MS4A1 (Rituximab Biosimilar)
-
Alternative Name
- Rituximab Biosimilar
-
Target Type
- Biosimilar
Target
-